Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care

Anthony T. Corcoran; Marc C. Smaldone; Brian L. Egleston; Jay Simhan; Serge Ginzburg; Todd M. Morgan; John Walton; David Y.T. Chen; Rosalia Viterbo; Richard E. Greenberg; Robert G. Uzzo; Alexander Kutikov

doi:10.1111/bju.12220

Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care

Anthony T. Corcoran, Marc C. Smaldone, Brian L. Egleston, Jay Simhan, Serge Ginzburg, Todd M. Morgan, John Walton, David Y.T. Chen, Rosalia Viterbo, Richard E. Greenberg, Robert G. Uzzo, Alexander Kutikov

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Objective To evaluate prostate cancer diagnosis rates and survival outcomes in patients receiving unrelated (non-prostate) urological care with those in patients receiving non-urological care. Materials and Methods We conducted a population-based study using the Surveillance Epidemiology and End Results (SEER) database to identify men who underwent surgical treatment of renal cell carcinoma (RCC; n = 18 188) and colorectal carcinoma (CRC; n = 45 093) between 1992 and 2008. Using SEERstat software to estimate standardized incidence ratios (SIRs), we investigated rates of prostate cancer diagnosis in patients with RCC and patients with CRC. Adjusting for patient age, race and year of diagnosis on multivariate analysis, we used Cox and Fine and Gray proportional hazards regressions to evaluate overall and disease-specific survival endpoints. Results The observed incidence of prostate cancer was higher in both the patients with RCC and those with CRC: SIR = 1.36 (95% confidence interval [CI] 1.27-1.46) vs 1.06 (95% CI 1.02-1.11). Adjusted prostate cancer SIRs were 30% higher (P < 0.001) in patients with RCC. Overall (hazard ratio = 1.13, P < 0.001) and primary cancer-adjusted mortalities (sub-distribution Hazard Ratio (sHR) = 1.17, P < 0.001) were higher in patients with RCC with no significant difference in prostate cancer-specific mortality (sHR = 0.827, P = 0.391). Conclusion Rates of prostate cancer diagnosis were higher in patients with RCC (a cohort with unrelated urological cancer care) than in those with CRC. Despite higher overall mortality in patients with RCC, prostate cancer-specific survival was similar in both groups. Opportunities may exist to better target prostate cancer screening in patients who receive non-prostate-related urological care. Furthermore, urologists should not feel obligated to perform prostate-specific antigen screening for all patients receiving non-prostate-related urological care.

Original language	English
Pages (from-to)	161-168
Number of pages	8
Journal	BJU International
Volume	112
Issue number	2
DOIs	https://doi.org/10.1111/bju.12220
State	Published - Jul 2013

Keywords

Adult
Aged
Aged, 80 and over
Carcinoma, Renal Cell/complications
Colorectal Neoplasms/complications
Humans
Kidney Neoplasms/complications
Male
Middle Aged
Prostatic Neoplasms/diagnosis
Retrospective Studies
Survival Rate

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bju.12220

Cite this

Corcoran, A. T., Smaldone, M. C., Egleston, B. L., Simhan, J., Ginzburg, S., Morgan, T. M., Walton, J., Chen, D. Y. T., Viterbo, R., Greenberg, R. E., Uzzo, R. G., & Kutikov, A. (2013). Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU International, 112(2), 161-168. https://doi.org/10.1111/bju.12220

@article{95177beb1cfd4ae4af8ad0a4b59e76c1,

title = "Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care",

abstract = "Objective To evaluate prostate cancer diagnosis rates and survival outcomes in patients receiving unrelated (non-prostate) urological care with those in patients receiving non-urological care. Materials and Methods We conducted a population-based study using the Surveillance Epidemiology and End Results (SEER) database to identify men who underwent surgical treatment of renal cell carcinoma (RCC; n = 18 188) and colorectal carcinoma (CRC; n = 45 093) between 1992 and 2008. Using SEERstat software to estimate standardized incidence ratios (SIRs), we investigated rates of prostate cancer diagnosis in patients with RCC and patients with CRC. Adjusting for patient age, race and year of diagnosis on multivariate analysis, we used Cox and Fine and Gray proportional hazards regressions to evaluate overall and disease-specific survival endpoints. Results The observed incidence of prostate cancer was higher in both the patients with RCC and those with CRC: SIR = 1.36 (95% confidence interval [CI] 1.27-1.46) vs 1.06 (95% CI 1.02-1.11). Adjusted prostate cancer SIRs were 30% higher (P < 0.001) in patients with RCC. Overall (hazard ratio = 1.13, P < 0.001) and primary cancer-adjusted mortalities (sub-distribution Hazard Ratio (sHR) = 1.17, P < 0.001) were higher in patients with RCC with no significant difference in prostate cancer-specific mortality (sHR = 0.827, P = 0.391). Conclusion Rates of prostate cancer diagnosis were higher in patients with RCC (a cohort with unrelated urological cancer care) than in those with CRC. Despite higher overall mortality in patients with RCC, prostate cancer-specific survival was similar in both groups. Opportunities may exist to better target prostate cancer screening in patients who receive non-prostate-related urological care. Furthermore, urologists should not feel obligated to perform prostate-specific antigen screening for all patients receiving non-prostate-related urological care.",

keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell/complications, Colorectal Neoplasms/complications, Humans, Kidney Neoplasms/complications, Male, Middle Aged, Prostatic Neoplasms/diagnosis, Retrospective Studies, Survival Rate",

author = "Corcoran, {Anthony T.} and Smaldone, {Marc C.} and Egleston, {Brian L.} and Jay Simhan and Serge Ginzburg and Morgan, {Todd M.} and John Walton and Chen, {David Y.T.} and Rosalia Viterbo and Greenberg, {Richard E.} and Uzzo, {Robert G.} and Alexander Kutikov",

note = "{\textcopyright} 2013 BJU International.",

year = "2013",

month = jul,

doi = "10.1111/bju.12220",

language = "English",

volume = "112",

pages = "161--168",

journal = "BJU International",

issn = "1464-4096",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care

AU - Corcoran, Anthony T.

AU - Smaldone, Marc C.

AU - Egleston, Brian L.

AU - Simhan, Jay

AU - Ginzburg, Serge

AU - Morgan, Todd M.

AU - Walton, John

AU - Chen, David Y.T.

AU - Viterbo, Rosalia

AU - Greenberg, Richard E.

AU - Uzzo, Robert G.

AU - Kutikov, Alexander

PY - 2013/7

Y1 - 2013/7

N2 - Objective To evaluate prostate cancer diagnosis rates and survival outcomes in patients receiving unrelated (non-prostate) urological care with those in patients receiving non-urological care. Materials and Methods We conducted a population-based study using the Surveillance Epidemiology and End Results (SEER) database to identify men who underwent surgical treatment of renal cell carcinoma (RCC; n = 18 188) and colorectal carcinoma (CRC; n = 45 093) between 1992 and 2008. Using SEERstat software to estimate standardized incidence ratios (SIRs), we investigated rates of prostate cancer diagnosis in patients with RCC and patients with CRC. Adjusting for patient age, race and year of diagnosis on multivariate analysis, we used Cox and Fine and Gray proportional hazards regressions to evaluate overall and disease-specific survival endpoints. Results The observed incidence of prostate cancer was higher in both the patients with RCC and those with CRC: SIR = 1.36 (95% confidence interval [CI] 1.27-1.46) vs 1.06 (95% CI 1.02-1.11). Adjusted prostate cancer SIRs were 30% higher (P < 0.001) in patients with RCC. Overall (hazard ratio = 1.13, P < 0.001) and primary cancer-adjusted mortalities (sub-distribution Hazard Ratio (sHR) = 1.17, P < 0.001) were higher in patients with RCC with no significant difference in prostate cancer-specific mortality (sHR = 0.827, P = 0.391). Conclusion Rates of prostate cancer diagnosis were higher in patients with RCC (a cohort with unrelated urological cancer care) than in those with CRC. Despite higher overall mortality in patients with RCC, prostate cancer-specific survival was similar in both groups. Opportunities may exist to better target prostate cancer screening in patients who receive non-prostate-related urological care. Furthermore, urologists should not feel obligated to perform prostate-specific antigen screening for all patients receiving non-prostate-related urological care.

AB - Objective To evaluate prostate cancer diagnosis rates and survival outcomes in patients receiving unrelated (non-prostate) urological care with those in patients receiving non-urological care. Materials and Methods We conducted a population-based study using the Surveillance Epidemiology and End Results (SEER) database to identify men who underwent surgical treatment of renal cell carcinoma (RCC; n = 18 188) and colorectal carcinoma (CRC; n = 45 093) between 1992 and 2008. Using SEERstat software to estimate standardized incidence ratios (SIRs), we investigated rates of prostate cancer diagnosis in patients with RCC and patients with CRC. Adjusting for patient age, race and year of diagnosis on multivariate analysis, we used Cox and Fine and Gray proportional hazards regressions to evaluate overall and disease-specific survival endpoints. Results The observed incidence of prostate cancer was higher in both the patients with RCC and those with CRC: SIR = 1.36 (95% confidence interval [CI] 1.27-1.46) vs 1.06 (95% CI 1.02-1.11). Adjusted prostate cancer SIRs were 30% higher (P < 0.001) in patients with RCC. Overall (hazard ratio = 1.13, P < 0.001) and primary cancer-adjusted mortalities (sub-distribution Hazard Ratio (sHR) = 1.17, P < 0.001) were higher in patients with RCC with no significant difference in prostate cancer-specific mortality (sHR = 0.827, P = 0.391). Conclusion Rates of prostate cancer diagnosis were higher in patients with RCC (a cohort with unrelated urological cancer care) than in those with CRC. Despite higher overall mortality in patients with RCC, prostate cancer-specific survival was similar in both groups. Opportunities may exist to better target prostate cancer screening in patients who receive non-prostate-related urological care. Furthermore, urologists should not feel obligated to perform prostate-specific antigen screening for all patients receiving non-prostate-related urological care.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Renal Cell/complications

KW - Colorectal Neoplasms/complications

KW - Humans

KW - Kidney Neoplasms/complications

KW - Male

KW - Middle Aged

KW - Prostatic Neoplasms/diagnosis

KW - Retrospective Studies

KW - Survival Rate

UR - http://www.scopus.com/inward/record.url?scp=84879636592&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000320930200026&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1111/bju.12220

DO - 10.1111/bju.12220

M3 - Article

C2 - 23795784

SN - 1464-4096

VL - 112

SP - 161

EP - 168

JO - BJU International

JF - BJU International

IS - 2

ER -

Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this